New therapeutic strategies in HCV: polymerase inhibitors

Authors


Correspondence

Stefan Zeuzem, MD, Professor of Medicine, Chief \x96 Department of Medicine I, J.W. Goethe University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany

Tel: +49 (0)69 6301 6899 or 4544

Fax: +49 (0)69 6301 6448

e-mail: Zeuzem@em.uni-frankfurt.de

Abstract

The characterization of the viral life cycle facilitated the development of directly acting antiviral drugs. Among those, several inhibitors of the viral RNA-dependent RNA polymerase have proven effectiveness in clinical trials. The characteristics of different nucleos(t)ide and non-nucleoside polymerase inhibitors, as well as their clinical applications and combinations with other classes of directly acting antiviral drugs are reviewed herein.

Ancillary